Janney Montgomery Scott’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$242K Sell
3,220
-1,155
-26% -$74.2K ﹤0.01% 2880
2026
Q1
$247K Buy
+4,375
New +$285K ﹤0.01% 2518
2025
Q1
Sell
-5,147
Closed -$402K 2743
2024
Q4
$402K Buy
+5,147
New +$413K ﹤0.01% 2133
2021
Q3
Sell
-9,022
Closed -$601K 2323
2021
Q2
$601K Sell
9,022
-7,598
-46% -$538K ﹤0.01% 1534
2021
Q1
$1.84M Sell
16,620
-1,694
-9% -$210K 0.01% 926
2020
Q4
$2.17M Sell
18,314
-1,391
-7% -$150K 0.01% 835
2020
Q3
$1.72M Buy
+19,705
New +$1.72M 0.01% 855
2018
Q3
Sell
-23,453
Closed -$2.1M 2089
2018
Q2
$2.1M Sell
23,453
-17,008
-42% -$1.44M 0.02% 661
2018
Q1
$2.96M Sell
40,461
-8,203
-17% -$563K 0.03% 517
2017
Q4
$2.83M Sell
48,664
-2,592
-5% -$136K 0.03% 520
2017
Q3
$2.3M Buy
51,256
+1,879
+4% +$78.1K 0.03% 553
2017
Q2
$1.95M Buy
49,377
+32,369
+190% +$1.33M 0.02% 584
2017
Q1
$690K Sell
17,008
-57
-0.3% -$2.23K 0.01% 1013
2016
Q4
$686K Buy
+17,065
New +$643K 0.01% 950

Other funds holding HAE

Janney Montgomery Scott's HAE Position: Q2 2026 in Review

Janney Montgomery Scott reduced its Haemonetics (HAE) stake by 26% in Q2 2026, selling an estimated $74.2K and leaving 3,220 shares worth $242K. The position accounts for ﹤0.01% of the portfolio, ranked #2880.

Janney Montgomery Scott first reported a position in HAE in Q4 2016 and has held it in 14 quarters since. The position peaked at $2.96M in Q1 2018. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Janney Montgomery Scott held 3,220 shares of Haemonetics worth $242K as of Q2 2026.
  • Janney Montgomery Scott sold 1,155 Haemonetics shares in Q2 2026, an estimated $74.2K.
  • Haemonetics made up ﹤0.01% of Janney Montgomery Scott's portfolio in Q2 2026, its #2880 holding.
  • Janney Montgomery Scott first reported a position in Haemonetics in Q4 2016 and has held it in 14 quarters since.
  • Janney Montgomery Scott's Haemonetics position peaked at $2.96M in Q1 2018.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Janney Montgomery Scott's 13F filing for Q2 2026, filed 5 Aug 2026.